Axillary lymph node dissection for intraductal breast carcinoma-is it indicated?
β Scribed by Melvin J. Silverstein; Robert J. Rosser; Eugene D. Gierson; James R. Waisman; Parvis Gamagami; Robert S. Hoffman; Aaron G. Fingerhut; Bernard S. Lewinsky; William Colburn; Neal Handel
- Publisher
- John Wiley and Sons
- Year
- 1987
- Tongue
- English
- Weight
- 603 KB
- Volume
- 59
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
β¦ Synopsis
One hundred patients with intraductal breast carcinoma (DCIS) were treated with either mastectomy (49 patients) or radiation therapy (51 patients). All patients underwent axillary lymph node dissection (average number of nodes removed, 16) as part of their treatment. No patient had any positive axillary lymph nodes. There has been one recurrence in each treatment group (median follow-up, 27 months) and no deaths. Intraductal breast carcinoma has little potential for metastasis to axillary lymph nodes.
π SIMILAR VOLUMES
Axillary lymph node dissection for staging the axilla in breast carcinoma patients is associated with considerable morbidity, such as edema of the arm, pain, sensory disturbances, impairment of arm mobility, and shoulder stiffness. Sentinel lymph node biopsy electively removes the first lymph node,
## Abstract ## Background The axillary nodal status may influence the prognosis and the choice of adjuvant treatment of individual breast cancer patients. The variation in number of reported axillary lymph nodes and its effect on the axillary nodal stage were studied and the implications are discu